Ahead of a plethora of potential biosimilar Humira (adalimumab) products launching across the US in 2023, the latest recipient of an approved biosimilar to the world’s bestselling drug, Fresenius Kabi, has put much consideration into “how are we going to position ourselves as a long-term player in the market,” the German firm’s senior vice president for US biosimilars tells Generics Bulletin as part of an exclusive interview.
Fresenius Kabi: Adalimumab Customers Want Supply Guarantee, We Can Provide That
Interchangeability ‘More Of A Legal Connotation,’ Firm Tells Generics Bulletin
Following Fresenius Kabi’s approval in mid-December for the eighth and latest biosimilar Humira (adalimumab) product, the company’s senior vice president for biosimilars in the US spoke to Generics Bulletin about how it can stand out from the pack and why it is confident that it can succeed.
More from Biosimilars
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.
• By
Accord received positive opinions for its Prolia and Xgeva biosimilars at the latest meeting of the EMA’s CHMP. Meanwhile, Celltrion picked up a nod for another Stelara biosimilar, while Rechon Life Science withdrew an application for human insulin.
More from Products
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.